Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A-Rearranged BCP-ALL

Minimal residual disease (MRD) is the most important outcome predictor in B precursor acute lymphoblastic leukemia (B-ALL), but additional contributing factors are poorly understood. To address the molecular and functional underpinnings of MRD kinetics in KMT2A-rearranged (KMT2A-r) as high-risk disease across all age groups, we analyzed a cohort of 325 KMT2A-r BCP-ALL patients (0-89 years, median: 32 years; n = 59 infants, n = 67 pediatric, n = 179 adults, n = 20 NA).

Diagnostic samples were studied by integrating gene expression and gene fusion profiling (RNA-Seq; discovery cohort: n=148, validation cohort: n=177) with karyotyping (SNP-Arrays; n=113), ex-vivo drug-response profiling (n=62) and MRD measurements at follow-up (n=97). To unravel the cell of origin of KMT2A-r ALL, we used the machine learning classifier ALLCatchR to define developmental trajectories and fitted linear slopes on the enrichment across B-cell-developmental stages as a measure for cell stemness. Stemness scores were validated using IG-rearrangement patterns and surface marker expression (FACS). Patients were treated according to the AIEOP-BFM ALL/INTERFANT and GMALL study group protocols, with IG/TR MRD measurements performed in the central reference laboratories. Pediatric-inspired induction therapy protocols in adult patients with comparable MRD sampling time points in pediatric regimens allowed for kinetic definitions of MRD clearance (fast / intermediate / slow) across age groups.

Age did not affect the initial MRD clearance (p = 0.96), but the patient age was significantly correlated with the underlying driver gene fusion (p = 9.2e-7) and stemness (p = 1.9e-15); gene fusion and stemness were also interdependent (p= 2.2e-16). Thus, the dissection of these co-factors on MRD clearances is needed to allow a comprehensive understanding of this molecular interplay.

Considering the most frequent fusion partners of KMT2A, AFF1 (n=63; 65%), MLLT1 (n=16; 16.5 %), and MLLT3 (n=13; 13.5%), we observed a skewed distribution in the three MRD categories fast / intermediate / slow. KMT2A::AFF1-r cases predominantly showed an intermediate or slow MRD clearance compared to KMT2A::MLLT1 and KMT2A::MLLT3 cases (83%, 38% and 30% slow/intermediate clearance respectively, p = 0.001). Compared to slow/intermediate MRD clearance, ALLs with fast MRD clearance were significantly more mature (p = 0.0018), with closer proximity towards more mature B-precursor stages (Pre-B-II-Large p = 0.037; Pre-B-II-Small p = 0.0047) than towards Pro-B cell-stage (p = 0.0001). Stemness also differed between driver fusions with KMT2A::AFF1-r leukemias being less mature compared to KMT2A::MLLT3 and KMT2A::MLLT1-r ALLs (p = 2.2e-16).

Gene expression programs in KMT2A::AFF1 cases revealed highly proliferative, early-B-cell-developmental-stage like signatures, global activation of gene expression and silenced apoptosis and differentiation signals. In contrast, KMT2A::MLLT3 showed downregulation of proliferative signalling and up-regulation of more differentiated B-cell signalling compared to KMT2A::AFF1-r ALL.

To assess functional consequences, we analyzed ex-vivo drug response profiles of over 30 drugs on primary cells (n = 62 patients) and correlated the ex-vivo sensitivities with the patient's MRD clearance. MRD clearance correlated with the sensitivity to clinically relevant drugs (Dexamethasone p = 0.002; Daunorubicin p = 0.04, Doxorubicin p = 0.01, Vincristine p = 0.02, Asparaginase p = 0.01). In contrast, Venetoclax showed good response in most samples but no evident correlation with MRD clearance (p = 0.75).

Integrating the molecular, functional and metadata layers we detected two distinct gene expression clusters separating patients with faster and slower MRD clearance. Intriguingly, these clusters were most significantly associated with stemness (p < 2.2e-16), and to a lesser extent with age (p = 2.4e-11) and fusion (p = 0.0005), indicating that stemness has the strongest impact on MRD clearance.

This age-overriding integrated analysis reveals a complex interplay of the cell of origin, the underlying gene fusion, and the patient age-directing response to frontline therapy in KMT2A-r B-ALL and molecular insights into underlying signalling pathways may better guide adapted treatment innovations in KMT2A-r BCP-ALL.

Lenk:OSE Immunotherapeutics: Research Funding. Burmeister:Pfizer Inc.: Honoraria. Goekbuget:Amgen, Astra Zeneca, Autolus, Clinigen, Gilead, Incyte, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi, Servier: Consultancy, Honoraria, Other: Advisory board; Amgen, Clinigen, Incyte, Jazz Pharmaceuticals, Novartis, Pfizer, Servier: Research Funding. Brüggemann:Amgen Becton Dickinson AstraZeneca Jazz,Pfizer: Consultancy, Honoraria, Research Funding, Speakers Bureau. Schrappe:JazzPharma, Servier, Amgen: Honoraria, Research Funding, Speakers Bureau. Cario:Jazz Pharmaceuticals: Other: travel support. Baldus:Janssen, Astellas, Pfizer, Astrazeneca, Servier, BMS: Consultancy, Honoraria.